• Artificial intelligence
• Biostatistics
• Chronic viral hepatitis
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Routinely collected health data

Since 2014, Terry Yip has been devoted to real-world big clinical data research to understand the epidemiology, natural history, assessment, treatment, and clinical outcome prediction of chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) through rigorous statistical analyses and big data analytics. He established one of the largest cohorts of patients with CHB who achieved hepatitis B surface antigen (HBsAg) seroclearance with long-term follow-up (J Hepatol 2017, 2018, 2019, 2023). He is a PI in the VCTE-Prognosis study, an international multicenter cohort study currently involving 16 centers with 18,000 patients with MASLD, focusing on non-invasive tests including vibration-controlled transient elastography (VCTE) and other serum-based biomarkers for long-term clinical outcome predictions (JAMA 2024, J Hepatol 2025, Gut 2025, Clinical and Molecular Hepatology 2025, Hepatology 2025).

Terry Yip obtained his BSc in Statistics with First Class Honours, MPhil in Risk Management Science, and Ph.D. in Medical Sciences from The Chinese University of Hong Kong (CUHK). During his Ph.D., he served as a visiting research fellow at the Department of Epidemiology and Public Health, University of Maryland, Baltimore. He is now an Associate Professor of the Department of Medicine and Therapeutics, CUHK, and the Co-Director (Data Science) of the CUHK Medical Data Analytics Centre. He now has over 250 publications in peer-reviewed journals.

Terry currently serves as Associate Editor of the Journal of Hepatology, Statistical Editor of Clinical and Molecular Hepatology, and Editorial Board Member of Clinical Gastroenterology and Hepatology, JHEP Reports, Alimentary Pharmacology and Therapeutics, and Hepatology Communications. He served as a Baveno VIII panelist on cirrhosis recompensation and is serving as the Communication Lead of the AASLD HBV/HDV Special Interest Group. He has served as a Council Member of The Hong Kong Association for the Study of Liver Diseases since 2021 and is now the Treasurer. He has been a Course Coordinator of the AASLD-APASL Young Investigator Workshop since 2024. He has been an invited speaker for regional and international conferences, including the AASLD, EASL, and APASL annual meetings, Global Hepatitis Summit, and Asian Pacific Digestive Week.

1. Top 2% Scientists, Stanford University (2022 – 2025)
2. Best Poster Presentation Award: Viral Hepatitis – Clinical, European Association for the Study of the Liver (EASL) (2024)
3. Young Investigator Award, Asian Pacific Association for the Study of the Liver (APASL) (2018, 2022, 2023)
4. Early Career Investigator Award in Clinical/Translational Science, American Association for the Study of Liver Diseases (AASLD) (2020)

1. Zhang Y, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gomez M, Kim SU, Wong VW, Castéra L, Yip TC. Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;84(1):175-190. doi:10.1097/HEP.0000000000001658.
2. Rabbat J, Yang B, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GBB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Fournier-Poizat C, Wong GLH, Zoncape M, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MSW, Canivet CM, Romero-Gomez M, Wong VWS, Kim SU, Yip TCF. Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement. Clin Mol Hepatol. 2026;32(1):289-304. doi:10.3350/cmh.2025.0888.
3. Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KK, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025;74(12):2050-2057. doi:10.1136/gutjnl-2025-334981.
4. Hui VW, Wong GL, Dai J, Tse YK, Lai MS, Lai JC, Chan HL, Wong VW, Yip TC. Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection. Hepatology. 2026;83(1):156-168. doi:10.1097/HEP.0000000000001354.
5. Yip TCF, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GBB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Fournier-Poizat C, Wong GLH, Pennisi G, Armandi A, Nakajima A, Wong VWS. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83(2):304-314. doi:10.1016/j.jhep.2025.01.014.
6. Lai JCT, Wong GLH, Tse YK, Hui VWK, Lai MSM, Chan HLY, Wong VWS, Yip TCF. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis. J Hepatol. 2025;82(6):992-1003. doi:10.1016/j.jhep.2024.11.018.
7. Hur MH, Yip TCF, Kim SU, Lee HW, Lee HA, Lee HC, Wong GLH, Wong VWS, Park JY, Ahn SH, Kim BK, Kim HY, Seo YS, Shin H, Park J, Ko Y, Park Y, Lee YB, Yu SJ, Lee SH, Kim YJ, Yoon JH, Lee JH. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B. J Hepatol. 2025;82(2):235-244. doi:10.1016/j.jhep.2024.08.016.
8. Lin H, Lee HW, Yip TCF, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GBB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Harrison SA, Fournier-Poizat C, Wong GLH, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MSW, Canivet CM, Romero-Gomez M, Kim SU, Wong VWS; VCTE-Prognosis Study Group. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA. 2024;331(15):1287-1297. doi:10.1001/jama.2024.1447.
9. Yip TCF, Lai JCT, Yam TF, Tse YK, Hui VWK, Lai MSM, Chan HLY, Wong VWS, Wong GLH. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B. J Hepatol. 2024;80(4):553-563. doi:10.1016/j.jhep.2023.12.001.
10. Lin H, Li G, Delamarre A, Ahn SH, Zhang X, Kim BK, Liang LY, Lee HW, Wong GLH, Yuen PC, Chan HLY, Chan SL, Wong VWS, de Lédinghen V, Kim SU, Yip TCF.A liver stiffness–based etiology-independent machine learning algorithm to predict hepatocellular carcinoma.Clin Gastroenterol Hepatol. 2024;22(3):602-610.e7. doi:10.1016/j.cgh.2023.11.005.
11. Zhang X, Yip TCF, Wong GLH, Leow WX, Liang LY, Lim LL, Li G, Ibrahim L, Lin H, Lai JCT, Chim AML, Chan HLY, Kong APS, Chan WK, Wong VWS. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: A randomised controlled trial. Gut. 2023;72(12):2364-2371. doi:10.1136/gutjnl-2023-330269.
12. Yip TCF, Tse YK, Lai MSM, Hui VWK, Li G, Lin H, Liang LY, Lai JCT, Wong GLH, Wong VWS. Diabetes mellitus impacts on the performance of hepatocellular carcinoma risk scores in chronic hepatitis B patients. Clin Gastroenterol Hepatol. 2023;21(11):2864-2875.e16. doi:10.1016/j.cgh.2023.02.004.
13. Yip TCF, Wong VWS, Lai MSM, Lai JCT, Hui VWK, Liang LY, Tse YK, Chan HLY, Wong GLH.Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol. 2023;78(3):524-533. doi:10.1016/j.jhep.2022.11.020.
14. Yip TCF, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GLH, Adams LA, de Lédinghen V, Sookoian S, Wong VWS. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology. 2023;77(4):1404-1427. doi:10.1002/hep.32774.
15. Yip TCF, Lee HW, Chan WK, Wong GLH, Wong VWS. Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76(3):726-734. doi:10.1016/j.jhep.2021.09.024.
16. Yip TCF, Wong VWS, Chan HLY, Tse YK, Lui GCY, Wong GLH. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158(1):215-225.e6. doi:10.1053/j.gastro.2019.09.025.
17. Yip TCF, Wong GLH, Chan HLY, Tse YK, Liang LY, Lai MSM, Jiang X, Wong VWS. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70(3):361-370. doi:10.1016/j.jhep.2018.10.014
18. Yip TCF, Wong VWS, Chan HLY, Tse YK, Kong APS, Lam KLY, Lui GCY, Wong GLH. Effects of diabetes and glycemic control on risk of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol. 2018;16(5):765-773.e2. doi:10.1016/j.cgh.2017.12.009.
19. Yip TCF, Wong GLH, Wong VWS, Tse YK, Lui GCY, Lam KLY, Chan HLY. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2018;68(1):63-72. doi:10.1016/j.jhep.2017.09.018.
20. Yip TCF, Chan HLY, Wong VWS, Tse YK, Lam KLY, Wong GLH. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 2017;67(5):902-908. doi:10.1016/j.jhep.2017.06.019.